STL Index for: Metronidazole
This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.
The etiology of papulopustular rosacea (PPR) is not well understood yet appears to involve both the innate and adaptive immune response in addition to possible infestation with Demodex mites. This article reviews data on Ivermectin cream 1%, a new topical treatment for PPR.
An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.
Update on drugs Metronidazole 1.3% vaginal gel (Actavis plc), Ecallantide for SC injection (Kalbitor®), Dalbavancin for IV injection (Dalvance™), Taliglucerase alfa for IV injection (Elelyso™), and Efinaconazole 10% topical solution (Jublia®)
Rosacea is a common, chronic cutaneous condition that affects the face. This article reviews a variety of treatments for treatments for rosacea, including topical and systemic therapies.
Rosacea is a common chronic skin disorder that has significant impact on the quality of life of affected individuals. Research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.
Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.
Novel uses of old medications and new formulations of systemic medications have broadened the therapeutic armamentarium for treating rosacea patients. It is of primary importance to offer patients safe and effective therapies for this chronic and incurable condition, improving both the clinical and psychosocial consequences of rosacea.
Today, diagnosing and treating rosacea remains a challenge. More studies are necessary to provide additional insight on drugs currently available as well as possible future agents. The ultimate goal is to provide each patient with a treatment regimen best suited for his or her individual needs.
Topical metronidazole has been used for the treatment of rosacea for over 30 years. Several placebo-controlled trials have demonstrated its effectiveness in the treatment of moderate-to-severe rosacea.
There are currently no laboratory tests to diagnose rosacea; it remains a clinical diagnosis. The actual pathophysiology and etiology of rosacea also remain unclear; however, quite recently the spectrum of rosacea has been classified and standardized.
Use of medications by breast-feeding mothers is not uncommon. Information regarding the safety of common dermatological medications during lactation will be reviewed. Based on this information, treatment recommendations will be made.
Rosacea is relatively common, typically occurring in individuals of Northern European and Celtic origin between 30 and 50 years of age. It is more common in women, but may be more severe in men. Currently there is no cure available for rosacea, but it can be controlled with topical and oral drug therapy.
A New Formulation Containing Sunscreen (SPF-15) And 1% Metronidazole (ROSASOL Cream) In The Treatment Of Rosacea
ROSASOL Cream is a novel topical formulation of 1% metronidazole in a vehicle containing sunscreens (SPF 15). This product has demonstrated efficacy in the treatment of inflammatory lesions, erythema, and telangiectasiae associated with rosacea.